Healthcare & Life Sciences
TRIMTECH Therapeutics
United Kingdom
activeseed
seed
Stage
2
Investors
About
TRIMTECH Therapeutics develops targeted protein degradation therapies to treat neurodegenerative diseases by eliminating toxic protein aggregates while preserving healthy proteins, leveraging the E3 ubiquitin ligase TRIM21.
Explore TRIMTECH Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.